This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Trontinemab showed significant amyloid plaque reduction in Alzheimer's, validating Brainshuttle technology and prompting a phase 3 study. MindMed initiated a phase 3 study of MM120 for major depressive disorder, with results expected in the second half of 2026. Results are expected in 2026.
SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals. Health care professionals should monitor the child’s growth and development and provide necessary interventions to mitigate weight loss.” FDA Drug Safety Communication.
Do you have practice tips to offer your fellow mentalhealth clinicians? Goodman, MD August 1st 2025 FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD Leah Kuntz August 1st 2025 ADHD With Bipolar Disorder: Genetics, Diagnosis, and New Thinking on Treatment David N.
Emerging research on RNA biomarkers, AI applications, and genetic mutations shows promise for developing new diagnostic tools for bipolar disorder. 2 With the potential benefits of developing lab-based diagnostic tools, there are unfortunately no definitive blood tests for bipolar disorder currently.
PTSD diagnosis requires nuanced understanding, as symptoms often overlap with other psychiatric disorders, complicating discernment. Genetic links between PTSD and migraines suggest shared pathways, with genes DAPK2 and TM6SF2 implicated in both disorders.
Related Videos Related Content Advertisement June 17th 2025 ADHD With Bipolar Disorder: Genetics, Diagnosis, and New Thinking on Treatment David N. Newsletter Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients. Subscribe Now!
Overview of Attention Deficit/Hyperactivity Disorder EP: 2. Role of Pediatricians in Diagnosing ADHD ADHD risk factors encompass both genetic and environmental components that significantly impact child development. ADHD in Elementary School Age Child: Patient Case 1 EP: 3. ADHD Diagnosis Criteria EP: 4. Risk Factors for ADHD EP: 7.
Both medications carry important safety considerations including potential for increased suicidal ideation, requiring careful monitoring and education about distinguishing medication-related intrusive thoughts from situational mentalhealth concerns. Subscribe Now!
1 The newly announced CNPV pathway was introduced by FDA Commissioner Marty Makary, MD, MPH, on June 17, 2025, and is intended to expedite reviews for medications that address US public health priorities. The CNPV program, introduced by FDA Commissioner Marty Makary, aims to reduce review times to 1-2 months for eligible applications.
Studies in Australia and the United States followed individuals with subthreshold psychotic symptoms and functional decline, along with a genetic risk for schizophrenia, over time. The DSM-5 task force concluded that there was not enough evidence to justify incorporating APS as an official mentaldisorder diagnosis in Section II.
Before reaching specialized behavioral health services, families typically consult pediatricians who must possess comprehensive knowledge of ADHD presentation, diagnostic criteria, and evidence-based treatment approaches. Subscribe Now!
A Brief Group Social-Belonging Intervention to Improve Mental-Health and Academic Outcomes in BIPOC and First-Generation-to-College Students Erin S. Understanding Ethnoracial Disparities and Advancing MentalHealth Equity Through Clinical Psychological Science: Introduction to Special Issue P. Pritchard, Jennifer L.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content